The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Eli Lilly said an experimental drug nearly eliminated an inherited type of bad cholesterol at its highest dose in a mid-stage study. Eli Lilly on Sunday said the Phase 2 study of lepodisiran ...

Novartis drug Pelacarsen that targets Lp(a) cholesterol is in global phase 3 trials. Last year, the company launched ...

Eli Lilly has linked lepodisiran to sustained ... The phase 2 trial tested the effect of lepodisiran on lipoprotein(a) (Lp(a)). Studies suggest up to 2 billion people globally have elevated ...

April 2 (UPI) --Heart disease experts are hailing the results of a clinical trial that showed a strongly positive performance by Eli Lilly's drug ... variant known as lipoprotein (a).

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated 1.4 billion people worldwide, including 64 million people in the U.S.

Eli Lilly and Company (NYSE ... therapy designed to lower the production of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease. In the Phase 2 ALPACA study, lepodisiran ...

Eli Lilly (NYSE:LLY) experienced a 6% increase in price over the last quarter, coinciding with several major developments. The company reported strong financial results, with significant ...

In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli ...

Eli Lilly on Sunday said the Phase 2 study of lepodisiran, designed to lower the production of lipoprotein(a), or lp(a), met its primary endpoint, reducing lp(a) levels by an average of 93.9% over ...